A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs MSB 0011359C (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 25 May 2017 Planned number of patients changed from 111 to 117.
- 25 Jan 2017 Planned End Date changed from 1 Aug 2019 to 1 Mar 2019.
- 25 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 1 May 2018.